Optieum Biotechnologies
OB is a biotechnology company committed to developing innovative scFv antibody-based therapies for the treatment of patients with cancers.
Optieum Biotechnologies is a company in biotechnology based in Asia-Pacific (APAC), founded in 2020.
Within the biotechnology space, the company focuses on its core offering rather than a broad product line.
The company is recorded as being based in Asia-Pacific (APAC).
It is recorded at the Seed stage.
Its team size is recorded as c_00001_00010 employees.
It has disclosed roughly $290M in funding.
| Sector | Biotechnology |
|---|---|
| Headquarters | Asia-Pacific (APAC) |
| Founded | 2020 |
| Employees | c_00001_00010 |
| Stage | seed |
| Total funding | $290,000,000 |
Website: optieumbio.com
Browse related
Emails and contact routes are reserved for registered members.
Create a free account
Create a free account